Literature DB >> 10933719

Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.

R G van Der Most1, K Murali-Krishna, R Ahmed, J H Strauss.   

Abstract

We have constructed a chimeric yellow fever/dengue (YF/DEN) virus, which expresses the premembrane (prM) and envelope (E) genes from DEN type 2 (DEN-2) virus in a YF virus (YFV-17D) genetic background. Immunization of BALB/c mice with this chimeric virus induced a CD8 T-cell response specific for the DEN-2 virus prM and E proteins. This response protected YF/DEN virus-immunized mice against lethal dengue encephalitis. Control mice immunized with the parental YFV-17D were not protected against DEN-2 virus challenge, indicating that protection was mediated by the DEN-2 virus prM- and E-specific immune responses. YF/DEN vaccine-primed CD8 T cells expanded and were efficiently recruited into the central nervous systems of DEN-2 virus challenged mice. At 5 days after challenge, 3 to 4% of CD8 T cells in the spleen were specific for the prM and E proteins, and 34% of CD8 T cells in the central nervous system recognized these proteins. Depletion of either CD4 or CD8 T cells, or both, strongly reduced the protective efficacy of the YF/DEN virus, stressing the key role of the antiviral T-cell response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933719      PMCID: PMC112342          DOI: 10.1128/jvi.74.17.8094-8101.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Nucleotide sequence of dengue 2 RNA and comparison of the encoded proteins with those of other flaviviruses.

Authors:  Y S Hahn; R Galler; T Hunkapiller; J M Dalrymple; J H Strauss; E G Strauss
Journal:  Virology       Date:  1988-01       Impact factor: 3.616

2.  Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.

Authors:  T P Monath; K Soike; I Levenbook; Z X Zhang; J Arroyo; S Delagrave; G Myers; A D Barrett; R E Shope; M Ratterree; T J Chambers; F Guirakhoo
Journal:  Vaccine       Date:  1999-04-09       Impact factor: 3.641

3.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

Authors:  J D Poland; C H Calisher; T P Monath; W G Downs; K Murphy
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

4.  Dengue virus structural differences that correlate with pathogenesis.

Authors:  K C Leitmeyer; D W Vaughn; D M Watts; R Salas; I Villalobos; C Ramos; R Rico-Hesse
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties.

Authors:  T J Chambers; A Nestorowicz; P W Mason; C M Rice
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein.

Authors:  R G van der Most; J Corver; J H Strauss
Journal:  Virology       Date:  1999-12-05       Impact factor: 3.616

Review 7.  Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade.

Authors:  S B Halstead
Journal:  Rev Infect Dis       Date:  1989 May-Jun

8.  Dengue virus premembrane and membrane proteins elicit a protective immune response.

Authors:  M Bray; C J Lai
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

Review 9.  Pathogenesis of dengue: challenges to molecular biology.

Authors:  S B Halstead
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

10.  Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus.

Authors:  A L Rothman; I Kurane; F A Ennis
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  23 in total

1.  Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2.

Authors:  Smita Jaiswal; Navin Khanna; S Swaminathan
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2.

Authors:  Iris Valdés; Lázaro Gil; Yaremis Romero; Jorge Castro; Pedro Puente; Laura Lazo; Ernesto Marcos; María G Guzmán; Gerardo Guillén; Lisset Hermida
Journal:  Clin Vaccine Immunol       Date:  2011-01-05

3.  West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy.

Authors:  Alexander G Pletnev; Robert Putnak; Jim Speicher; Eric J Wagar; David W Vaughn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

4.  Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.

Authors:  F Guirakhoo; J Arroyo; K V Pugachev; C Miller; Z X Zhang; R Weltzin; K Georgakopoulos; J Catalan; S Ocran; K Soike; M Ratterree; T P Monath
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.

Authors:  A G Pletnev; M Bray; K A Hanley; J Speicher; R Elkins
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Differential in vivo clearance and response to secondary heterologous infections by H2(b)-restricted dengue virus-specific CD8+ T cells.

Authors:  Coreen M Beaumier; Smita Jaiswal; Kim Y West; Heather Friberg; Anuja Mathew; Alan L Rothman
Journal:  Viral Immunol       Date:  2010-10       Impact factor: 2.257

7.  Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Authors:  F Guirakhoo; K Pugachev; Z Zhang; G Myers; I Levenbook; K Draper; J Lang; S Ocran; F Mitchell; M Parsons; N Brown; S Brandler; C Fournier; B Barrere; F Rizvi; A Travassos; R Nichols; D Trent; T Monath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.

Authors:  Flavio Lauretti; Anasuya Chattopadhyay; Rafael Freitas de Oliveira França; Luiza Castro-Jorge; John Rose; Benedito A L da Fonseca
Journal:  Hum Vaccin Immunother       Date:  2016-05-16       Impact factor: 3.452

Review 9.  Mouse models of dengue virus infection and disease.

Authors:  Lauren E Yauch; Sujan Shresta
Journal:  Antiviral Res       Date:  2008-07-09       Impact factor: 5.970

10.  An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.

Authors:  Laura J White; Melissa M Parsons; Alan C Whitmore; Brandon M Williams; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.